Interpace Diag Group (IDXG)

$0.78 -0.03 (-4.12%)
Market Cap 3.49M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 3,100
Avg Vol 7,524
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 25%
Beta 0.86
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Cujo
Cujo Sep. 3 at 2:22 AM
$IDXG
0 · Reply
Waters59
Waters59 Aug. 28 at 4:29 PM
$IDXG So many years, it's just numb. 😆 Sell the Company already!
0 · Reply
Waters59
Waters59 Aug. 21 at 2:37 PM
$IDXG
0 · Reply
Esau815
Esau815 Aug. 8 at 2:25 AM
$IDXG Very respectable quarter given the PancraGen overhang. Revenues are within 80% of what they were when PancraGen was around. Cash flow positive and cash flow will dramatically increase after the October 1 debt is extinguished. The PancraGen delay undoubtedly saved the company in that PE gave up their preference and a good chunk of the (then) $12MM debt got paid while it was around. Waiting for the Q. But with $3.3MM disclosed in July? We're talking revenues of close to $40MM without Pancragen. At 1.5 times revenues? That's about $60MM. 27MM shares. That's a bit over $2. I think that's we're sold and that's where I think we're going.
0 · Reply
apppro
apppro Aug. 7 at 8:10 PM
$IDXG
0 · Reply
apppro
apppro Aug. 7 at 8:08 PM
$IDXG Report hard to tell BUT looks good https://ir.interpace.com/press-releases/detail/243/interpace-biosciences-announces-second-quarter-2025
0 · Reply
Waters59
Waters59 Aug. 4 at 1:39 PM
$IDXG Tick-Tock...Not getting any younger! Where's management? PR?
0 · Reply
Waters59
Waters59 Jun. 16 at 1:59 PM
$IDXG Just no volume. Doesn't need much to change the direction. Just sell the company already and let the bleeding stop.
1 · Reply
AlphaTuna
AlphaTuna May. 23 at 12:34 AM
Lowest Volume Rated General Stocks Per 5/22/2025’s Close: 1 – $AHOTF 2 – $CAPC 3 – $AKTSQ 4 – $RDEXF 5 – $PAANF 6 – $FDVA 7 – $FNRN 8 – $IDXG 9 – $ARESF 10 – $CCM https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-5-22-2025/
0 · Reply
Esau815
Esau815 May. 22 at 12:56 PM
$IDXG I'm definitely wait and see on this one as I wait for the next Q. The next Q will be almost pure thyroid as PancraGen was discontinued April 24. Their guidance sort of indicates $8.5MM per Q thyroid sales. Assuming that's sort of on target--what will their EBITDA be? The closer to $2MM per Q the better though that might not be feasible. That's the number I'm looking at. They just missed out paying off the Broad Oak debt by about three months with PancraGen revenues. Those last months of delays were cruicial in getting that debt down. Too bad they couldn't have squeezed out a few more. Thanks to Ampersand/1315 giving up their preference this is definitely one that might have a doable outcome.
0 · Reply
Latest News on IDXG
No data available.
Cujo
Cujo Sep. 3 at 2:22 AM
$IDXG
0 · Reply
Waters59
Waters59 Aug. 28 at 4:29 PM
$IDXG So many years, it's just numb. 😆 Sell the Company already!
0 · Reply
Waters59
Waters59 Aug. 21 at 2:37 PM
$IDXG
0 · Reply
Esau815
Esau815 Aug. 8 at 2:25 AM
$IDXG Very respectable quarter given the PancraGen overhang. Revenues are within 80% of what they were when PancraGen was around. Cash flow positive and cash flow will dramatically increase after the October 1 debt is extinguished. The PancraGen delay undoubtedly saved the company in that PE gave up their preference and a good chunk of the (then) $12MM debt got paid while it was around. Waiting for the Q. But with $3.3MM disclosed in July? We're talking revenues of close to $40MM without Pancragen. At 1.5 times revenues? That's about $60MM. 27MM shares. That's a bit over $2. I think that's we're sold and that's where I think we're going.
0 · Reply
apppro
apppro Aug. 7 at 8:10 PM
$IDXG
0 · Reply
apppro
apppro Aug. 7 at 8:08 PM
$IDXG Report hard to tell BUT looks good https://ir.interpace.com/press-releases/detail/243/interpace-biosciences-announces-second-quarter-2025
0 · Reply
Waters59
Waters59 Aug. 4 at 1:39 PM
$IDXG Tick-Tock...Not getting any younger! Where's management? PR?
0 · Reply
Waters59
Waters59 Jun. 16 at 1:59 PM
$IDXG Just no volume. Doesn't need much to change the direction. Just sell the company already and let the bleeding stop.
1 · Reply
AlphaTuna
AlphaTuna May. 23 at 12:34 AM
Lowest Volume Rated General Stocks Per 5/22/2025’s Close: 1 – $AHOTF 2 – $CAPC 3 – $AKTSQ 4 – $RDEXF 5 – $PAANF 6 – $FDVA 7 – $FNRN 8 – $IDXG 9 – $ARESF 10 – $CCM https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-5-22-2025/
0 · Reply
Esau815
Esau815 May. 22 at 12:56 PM
$IDXG I'm definitely wait and see on this one as I wait for the next Q. The next Q will be almost pure thyroid as PancraGen was discontinued April 24. Their guidance sort of indicates $8.5MM per Q thyroid sales. Assuming that's sort of on target--what will their EBITDA be? The closer to $2MM per Q the better though that might not be feasible. That's the number I'm looking at. They just missed out paying off the Broad Oak debt by about three months with PancraGen revenues. Those last months of delays were cruicial in getting that debt down. Too bad they couldn't have squeezed out a few more. Thanks to Ampersand/1315 giving up their preference this is definitely one that might have a doable outcome.
0 · Reply
Benderama8
Benderama8 May. 10 at 2:09 AM
$IDXG I'm not sure what to think on this stock other than it's fairly valued at this point. If you include in the preferred shares converting into common, the outstanding shares would be around 29m. Assuming they can make about 1m a quarter, that puts this stock at a p/e of about 8.
1 · Reply
apppro
apppro May. 8 at 8:32 PM
$IDXG could be worse. not really so bad after all
0 · Reply
Waters59
Waters59 May. 2 at 3:47 PM
$IDXG umph, this 1 hurts. Wish their was a buyout of $4, though I need like $16. Hell, I'd take $2.
1 · Reply
Esau815
Esau815 May. 2 at 1:48 AM
$IDXG Quite a filing. "substantially offset"? One third of their revenues is about $16MM No way that the CEO is making a false filing. I consider this filing to be very good news. Let's see if the market agrees.
0 · Reply
Cujo
Cujo May. 1 at 11:09 PM
$IDXG The Company expects that the loss of PancraGEN® and related restructuring activities will reduce its annualized cost of revenue and operating expenses by approximately $12.5 million to $14.5 million which is expected to substantially offset the expected loss of approximately one-third of its revenues. The cost that the Company expects to incur in connection with the Restructuring Plan is subject to several assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring Plan.
0 · Reply
Esau815
Esau815 Apr. 25 at 3:25 PM
$IDXG Thought that Mr. Market had realized that PancraGen was likely dead before this. Was wrong about that. At this point? Thyroid has $27MM in revenue and CEO says IDXG is profitable without PancraGen. Remember. The preferreds GAVE UP THEIR PREFERENCE. So this will not be a zero. They own 81% of the common. Had they not converted this would be hopeless. At present prices? They have about $3MM in debt which shouldn't be onerous. Have to think that they will have a deal that will yield more than today's price.
1 · Reply
apppro
apppro Apr. 24 at 8:24 PM
$IDXG @InterpaceBio $IDXG Yeah well this sucks: "Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk" thought we had a chance. But CMS is a broken mess. This was expected really. They do say stay profitable and planned without it. so ...........
1 · Reply
crane_train21
crane_train21 Apr. 24 at 8:16 PM
$IDXG well that’s a problem.
1 · Reply
Waters59
Waters59 Apr. 24 at 6:02 PM
$IDXG no news...no volume...🚮
0 · Reply
Cujo
Cujo Apr. 8 at 5:03 PM
$IDXG finally some volume
0 · Reply
WAYWARD_SUN
WAYWARD_SUN Apr. 8 at 6:17 AM
$IDXG
0 · Reply
PenkeTrading
PenkeTrading Apr. 8 at 6:05 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Interpace Biosciences Inc. Is that bullish or bearish? $IDXG #RsiOversold #OTCQX
0 · Reply